ICCC logo

ImmuCell Stock Price

Symbol: NasdaqCM:ICCCMarket Cap: US$55.9mCategory: Pharmaceuticals & Biotech

ICCC Share Price Performance

US$6.18
2.43 (64.80%)
US$6.18
2.43 (64.80%)
Price US$6.18

ICCC Community Narratives

There are no narratives available yet.

Recent ICCC News & Updates

No updates

ImmuCell Corporation Key Details

US$27.3m

Revenue

US$17.9m

Cost of Revenue

US$9.4m

Gross Profit

US$9.7m

Other Expenses

-US$271.8k

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 15, 2025
Earnings per share (EPS)
-0.03
Gross Margin
34.45%
Net Profit Margin
-1.00%
Debt/Equity Ratio
35.1%

ImmuCell Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About ICCC

Founded
1982
Employees
71
CEO
Michael Brigham
WebsiteView website
immucell.com

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

U.S. Market Performance

  • 7 Days: -0.2%
  • 3 Months: 12.2%
  • 1 Year: 22.4%
  • Year to Date: 7.7%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading